{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-26-001211","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-09-09T21:17:37+00:00","discovered_at":"2026-09-09T21:18:00.496132+00:00","generated_at":"2026-09-09T21:18:05.056534+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Anavex gets FDA meeting to discuss pediatric inclusion in Rett syndrome Phase 3 trial","bullets":["FDA granted Anavex's request for a meeting to discuss adding pediatric patients to Phase 3 trial ANAVEX 2-73-RS-005 in Rett syndrome.","Disclosure made September 9, 2026; trial targets adult patients with ANAVEX 2-73 (blarcamesine).","Company prioritizing ANAVEX 2-73 development in early Alzheimer's, Rett, and Fragile X syndromes in the US.","Meeting could expand trial scope to pediatric population, a potential label-expansion step."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-001211","json":"https://secwatch.observer/filing/0001731122-26-001211.json","markdown":"https://secwatch.observer/filing/0001731122-26-001211.md","text":"https://secwatch.observer/filing/0001731122-26-001211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001211/0001731122-26-001211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001211/e7928_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T21:18:05.056534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}